Pazopanib

Generic Name
Pazopanib
Brand Names
Votrient
Drug Type
Small Molecule
Chemical Formula
C21H23N7O2S
CAS Number
444731-52-6
Unique Ingredient Identifier
7RN5DR86CK
Background

Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Indication

Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

Associated Conditions
Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
Associated Therapies
-

Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-03-09
Last Posted Date
2023-09-06
Lead Sponsor
ARCAGY/ GINECO GROUP
Target Recruit Count
118
Registration Number
NCT02383251
Locations
🇫🇷

Institut Bergonié, Bordeaux, France

🇫🇷

Hôpital Henri Duffaut, Avignon, France

🇫🇷

Centre Jean Perrin, Clermont-ferrand, France

and more 33 locations

Pazopanib for Treating Uterine Leiomyosarcoma

Phase 2
Withdrawn
Conditions
Interventions
First Posted Date
2015-03-04
Last Posted Date
2015-11-18
Lead Sponsor
Gynecologic Oncology Group
Registration Number
NCT02378142

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

Conditions
First Posted Date
2015-02-03
Last Posted Date
2021-02-15
Lead Sponsor
Tracon Pharmaceuticals Inc.
Registration Number
NCT02354612
Locations
🇺🇸

UCLA, Santa Monica, California, United States

Phase II Study of Pazopanib and Topotecan in Cervical Cancer

First Posted Date
2015-01-28
Last Posted Date
2016-08-16
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT02348398

Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2015-01-06
Last Posted Date
2024-05-06
Lead Sponsor
Centre Antoine Lacassagne
Target Recruit Count
51
Registration Number
NCT02331498
Locations
🇫🇷

Centre Antoine Lacassagne, Nice, Cedex 2, France

Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients

First Posted Date
2014-12-24
Last Posted Date
2014-12-24
Lead Sponsor
Southern China Urology Cancer Consortium
Target Recruit Count
86
Registration Number
NCT02324803
Locations
🇨🇳

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy

Phase 2
Completed
Conditions
Interventions
First Posted Date
2014-11-25
Last Posted Date
2020-08-05
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
56
Registration Number
NCT02300545
Locations
🇺🇸

University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States

🇺🇸

Northwestern University, Chicago, Illinois, United States

🇺🇸

Mayo Clinic - Phoenix, Phoenix, Arizona, United States

and more 4 locations

Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy

Completed
Conditions
Interventions
First Posted Date
2014-11-04
Last Posted Date
2018-04-26
Lead Sponsor
Spanish Oncology Genito-Urinary Group
Target Recruit Count
300
Registration Number
NCT02282579
Locations
🇪🇸

Hospital Provincial de Pontevedra, Pontevedra, Spain

🇪🇸

Hospital Universitario Virgen del Rocío, Sevilla, Spain

🇪🇸

Hospital Clínic de Barcelona, Barcelona, Spain

and more 31 locations

Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)

First Posted Date
2014-10-31
Last Posted Date
2016-10-14
Lead Sponsor
Spanish Oncology Genito-Urinary Group
Target Recruit Count
4
Registration Number
NCT02279576
Locations
🇪🇸

Complejo Hospitalario Regional Reina Sofía, Córdoba, Spain

🇪🇸

Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain

🇪🇸

Hospital Universitario Lucus Augusti, Lugo, Spain

and more 5 locations
© Copyright 2024. All Rights Reserved by MedPath